Earnings

C4 Therapeutics Q3 EPS $(0.16) Beats $(0.22) Estimate, Sales $8.468M Miss $8.514M Estimate

Nov 5, 2026 · 07:41 AM ET· updated 2h ago

C4 Therapeutics (NASDAQ:CCCC) reported quarterly losses of $(0.16) per share which beat the analyst consensus estimate of $(0.22) by 27.27 percent. This is a 63.64 percent increase over losses of $(0.44) per share from

Why It Matters

C4 Therapeutics lost less money than experts thought it would. But their sales fell short, so watch if they can grow revenue while spending less.

This read is generated by AI from raw market data and is for education only. It is not financial advice, not a signal, and not a recommendation to buy or sell.

Tickers in Play

CCCC3.00

-0.12 (-3.85%)

Last session drawn · prints held ~15 minutes · licensed exchange data

Source: Benzinga · Read the original report at the publisher. Headline and figures shown for context; data may be delayed.

Disclosure: Educational and informational purposes only. Not financial advice. We educate, not advise. Market data may be delayed up to 15 minutes unless marked real-time. Past performance is not indicative of future results.